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Aims: Myeloperoxidase (MPO) catalyzes the formation of a wide variety of oxidants, 27 
including hypochlorous acid (HOCl), and contributes to cardiovascular disease 28 
progression. We hypothesized that during its action MPO evokes substantional 29 
vasomotor responses. 30 
Methods: Following exposure to MPO (1.92 mU ml-1) in the presence of increasing 31 
concentrations of hydrogen peroxide (H2O2) changes in arteriolar diameter of isolated 32 
gracilis skeletal muscle arterioles (SMAs), and coronary arterioles (CAs) and in the 33 
isometric force in basilar arteries (BAs) of the rat were monitored.  34 
Results: MPO increased vascular tone to different degrees in CAs, SMAs and BAs. 35 
The mechanism of increased vasoconstriction was studied in detail in SMAs. MPO-36 
evoked vasoconstrictions were prevented by the MPO inhibitor 4-37 
aminobenzhydrazide (50 µM), by endothelium removal in the SMAs. Surprisingly, the 38 
HOCl scavenger L-methionine (100 µM), the thromboxane A2 (TXA2) antagonist SQ-39 
29548 (1 µM) or the nonspecific cyclooxygenase (COX) antagonist indomethacin (1 40 
µM) converted the MPO-evoked vasoconstrictions to pronounced vasodilations in 41 
SMAs; not seen in the presence of H2O2. In contrast to norepinephrine-induced 42 
vasoconstrictions, the MPO-evoked vasoconstrictions were not accompanied by 43 
significant increases in arteriolar [Ca2+] levels in SMAs. 44 
Conclusion: These data showed, H2O2-derived HOCl to be a potent vasoconstrictor 45 
upon MPO application. HOCl activated the COX pathway, causing the synthesis and 46 
release of TXA2-like substance to increase the Ca2+ sensitivity of the contractile 47 
apparatus in vascular smooth muscle cells and thereby to augment H2O2-evoked 48 




unmasked the effects of additional MPO-derived radicals with a marked vasodilatory 50 
potential in SMAs. 51 
Key words: hydrogen peroxide, myeloperoxidase, smooth muscle calcium, 52 
thromboxane A2, vasoconstrictions 53 
 54 
Introduction 55 
The effector enzyme myeloperoxidase (MPO) has a protective role in inflammatory 56 
processes. However, the activation of MPO may become deleterious and can also 57 
contribute to the development of cardiovascular diseases (Nicholls and Hazen, 2005, 58 
Podrez et al., 2000, Klebanoff, 2005). Accordingly, excessive levels of MPO in the 59 
plasma may be accompanied by an increased risk of subsequent cardiovascular 60 
events (Baldus et al., 2003, Zhang et al., 2001c, Vita et al., 2004, Brennan et al., 61 
2003, Karakas and Koenig, 2012, Kataoka et al., 2014), whereas individuals with an 62 
inherited MPO deficiency are at a reduced cardiovascular risk (Nikpoor et al., 2001, 63 
Hoy et al., 2001). There is currently no clear explanation of this situation. 64 
MPO, a heme-containing, intensely green protein, was originally isolated from 65 
canine pus and from purulent fluids from patients with tuberculosis (Klebanoff, 2005, 66 
Malle et al., 2007). The synthesis of MPO is initiated in the bone marrow during 67 
myeloid differentiation and is completed in the granulocytes (Lau and Baldus, 2006, 68 
Hansson et al., 2006). MPO is stored primarily in the azurophil granules of the 69 
polymorphonuclear neutrophils and monocytes, but it has also been found in tissue 70 
macrophages (Daugherty et al., 1994, Lau and Baldus, 2006, Hampton et al., 1998, 71 
Klebanoff, 2005). To exert its antimicrobial effects, MPO primarily catalyzes the 72 
reaction of hydrogen peroxide (H2O2) with chloride (Hampton et al., 1998), to form 73 
hypochlorous acid (HOCl) (Malle et al., 2007, Cook et al., 2012). The activation of 74 




peroxidase activity. The biological effects of the MPO (e.g. vasomotor activity, 76 
permeability, apoptotic effect) system depend on the local concentration of H2O2 77 
(Golubinskaya et al., 2014) of other substrates and/or antioxidant molecules (e.g. 78 
methionine (Met) (Podrez et al., 2000, Porszasz et al., 2002). Taken together, the 79 
involvement of MPO has been implicated in vascular inflammation in association with 80 
infection, diabetes and atherosclerosis (Malle et al., 2007, Cook et al., 2012, Zhang 81 
et al., 2004, Kataoka et al., 2014, Sugiyama et al., 2001, Sirpal, 2009, Woods et al., 82 
2003, Ford, 2010). 83 
It is not known at present how the persistent generation of MPO-derived 84 
oxidants evokes adverse effects in vascular tissues. MPO and its oxidative products 85 
are highly abundant in human atherosclerotic lesions (Daugherty et al., 1994, Hazen 86 
and Heinecke, 1997, Hazen et al., 2000, Hazell et al., 1996). MPO is presumed to be 87 
involved in the oxidative modification of low-density lipoprotein, thereby converting it 88 
into a high-uptake form and hence promoting foamy cell formation. (Podrez et al., 89 
1999, Savenkova et al., 1994) Through its catalytic activity, MPO can consume 90 
nitrogen monoxide (NO), thereby limiting its bioavailability (Eiserich et al., 2002, Abu-91 
Soud and Hazen, 2000). MPO-derived HOCl reacts with L-arginine and produces 92 
NO-synthesis inhibitors (Zhang et al., 2001b, Zhang et al., 2001a), and HOCl can 93 
impair endothelial NO bioactivity in a superoxide-dependent manner (Stocker et al., 94 
2004). Furthermore, MPO and HOCl can activate matrix metalloproteinases and 95 
deactivate matrix metalloproteinase inhibitors, leading to weakening of the fibrous 96 
cap and the development of destabilized atherosclerotic plaque (Karakas and 97 
Koenig, 2012, Fu et al., 2001). From a functional aspect, MPO treatment led to a 98 
decrease in myocardial perfusion in pigs and inhibited the acetylcholine-evoked 99 




response to acetylcholine was also found to be impaired in mice at relatively high 101 
plasma MPO levels (Zhang et al., 2013). Nevertheless, the mechanisms through, 102 
which MPO modulates the vascular responses are not well understood. In the 103 
present study, we made an effort to investigate the effects of MPO activation in 104 
vascular preparations in vitro. Moreover, we tried to characterize the possible 105 
mechanism of the vasomotor action of MPO in SMAs. 106 
Since the MPO substrate H2O2 was earlier identified as an important regulator 107 
of vascular diameter under both normal and pathological conditions, the vasoactive 108 
effects of MPO were contrasted to those of H2O2. H2O2 evokes a concentration-109 
dependent biphasic effect in the skeletal muscle arterioles (SMAs) and mesenteric 110 
arteries in the rat, causing vasoconstriction at lower concentrations, and vasodilation 111 
at higher concentrations (Gao et al., 2003, Cseko et al., 2004, Csato et al., 2014), 112 
whereas, H2O2 induces only vasodilation in the rat coronaries (Csato et al., 2014). 113 
In the present study, we investigated (i) the acute effects of MPO on the H2O2-114 
evoked changes in diameter in isolated SMAs and coronary arterioles (CAs) and on 115 
the contractile force in the basilar arteries (BAs) of the rat, and (ii) the signal 116 
transduction pathways mediating the vascular effects of MPO derived-oxidative 117 
radicals. 118 
 119 
Materials and Methods 120 
Animals, anesthesia and tissue dissection 121 
Male Wistar rats (weighing 250-350 g, 6-9 weeks old) obtained from Toxi-Coop 122 
Toxicological Research Center, Dunakeszi, Hungary) were fed a standard chow and 123 
drank tap water ad libitum. Anesthesia was performed with an intraperitoneal 124 




suffering of animals. The gracilis muscle, the heart and the brain were removed and 126 
placed into silicone-coated Petri dishes containing 0-4 ˚C Krebs solution (composition 127 
in mM: 110 NaCl, 5.0 KCl, 2.5 CaCl2, 1.0 MgSO4, 1.0 KH2PO4, 5.0 glucose and 24.0 128 
NaHCO3, obtained from Sigma-Aldrich, St. Louis, MO, USA) equilibrated with a 129 
gaseous mixture of 5% CO2, 10% O2 and 85% N2 at pH 7.4. All animal procedures 130 
used in this study were in full accordance with the rules of the Ethical Committee of 131 
the University of Debrecen and approved by the appropriate governmental body 132 
Directive 2010/63/EU of the European Parliament. The study is conforming with: 133 
Persson PB. Good Publication Practice in Physiology 2013 Guidelines for Acta 134 
Physiol (Oxf) (Persson, 2013). 135 
 136 
Materials and drugs 137 
The TXA2 inhibitor SQ-29548 was purchased from BioMarker Kft. (Gödöllő, 138 
Hungary). MPO protein, MPO inhibitor and COX antibodies were obtained from 139 
Abcam (Cambridge, UK). Secondary antibodies were from Jackson Immunoresearch 140 
Laboratories, Inc. (West Grove, PA, USA). All other chemicals were from Sigma-141 
Aldrich (St. Louis, MO, USA) and were kept under the conditions recommended by 142 
the manufacturer. All reported concentrations are cumulative concentrations in the 143 
organ chamber.  144 
 145 
Measurement of arteriolar diameter 146 
The rat SMAs and CAs were isolated and the changes in their diameters were 147 
mesaured as described earlier (Csato et al., 2014). Briefly, the isolated arterioles 148 
were transferred into an organ chamber and then were cannulated. The intraluminal 149 




Instrumentation, St. Albans, VT, USA). The temperature was maintained at 37 ˚C by 151 
the built in temperature controller in the tissue chamber (Living Systems 152 
Instrumentation, St. Albans, VT, USA). Changes in arteriolar diameter were recorded 153 
by a video microscope system (microscope: Nikon, Eclipse 80i; CCD camera: Topica 154 
Technology Co Ltd, Taipei, Taiwan; video digitalizer: National Institutes, Bethesda, 155 
USA). The isolated SMAs and CAs spontaneously developed a substantial myogenic 156 
tone (a decrease in diameter from 196±6 µm to 160±6 µm, n=45, and from 234±14 157 
µm to 178±14 µm, n=9, respectively) in response to an intraluminal pressure of 80 158 
mmHg.  159 
 160 
Measurement of arteriolar contractions under isometric conditions 161 
BAs were prepared from rat brains with microsurgical tools, and ~ 4-mm-long rings 162 
were then mounted in an isometric contraction measurement system (DMT-510, 163 
Danish Myotechnology, Aarhus, Denmark). Before exposure to test solutions, vessel 164 
tone was normalized. To this end, preparations were stretched at a force by 165 
increasing 1.5 mN every 15 s until the calculated intraluminal pressure reached 13.4 166 
kPa. The experiments were then performed at this stretch level (isometric 167 
contractions). 168 
 169 
Experimental protocols 170 
The endothelial function was tested with acetylcholine (1 nM-10 µM), and the smooth 171 
muscle function with norepinephrine (1 nM-10 µM, in SMAs), serotonin (1 nM-10 µM, 172 
in CAs) or potassium chloride (10-60 mM, in BAs). 173 
MPO activity was measured via detection of the chemiluminescence produced 174 




stabilized 30% stock solution (Sigma Aldrich, St. Louis, MO, USA) immediately 176 
before the experiments and were stored on ice. The arterioles were first treated with 177 
MPO (1.92 mU ml-1, 300 s treatment duration, diameter measured every 10 s) to 178 
record the effects of MPO alone. This was followed by the addition of H2O2 (1 µM-10
 
179 
mM) and the responses to MPO+H2O2 were then determined. In the BAs, the effects 180 
of MPO and H2O2 were tested after precontractions were evoked with 60 mM 181 
potassium chloride.  182 
The mechanism of MPO-evoked vasomotor responses was explored in detail 183 
in SMAs. In some experiments, the endothelium was removed by the perfusion of air 184 
bubbles through the arterioles (denudation). Successful endothelium denudation was 185 
verified by the loss of dilation in response to acetylcholine (10 μM, 96±4% dilation 186 
before and -6±4% after endothelium removal, n=5), while a maintained smooth 187 
muscle function was confirmed with norepinephrine (71±1% constriction before and 188 
64±2% after endothelium removal). The effects of MPO and H2O2 were also 189 
measured in the presence of an MPO inhibitor (50 µM 4-aminobenzhydrazide), a 190 
TXA2 receptor inhibitor (1 µM SQ-29548) and a COX antagonist (1 µM indomethacin) 191 
in the SMAs. The effects of MPO were tested after incubation of the vessels with the 192 
HOCl scavenger L-Met (20, 40 and 100 µM) in all three vessel types. At the end of 193 
the experiments, the maximal (passive) arteriolar diameter was determined in the 194 
absence of extracellular Ca2+.  195 
 196 






Simultaneous measurements of intracellular Ca2+ and arteriolar diameter were 200 
performed as described previously (Csato et al., 2014, Czikora et al., 2012, 201 
Kandasamy et al., 2013). Briefly, SMAs were isolated and cannulated as mentioned 202 
above, except that the tissue bath was supplemented with 1% bovine serum albumin 203 
(Sigma Aldrich, St. Louis, MO, USA) and 5 µM Fura-2AM, a ratiometric fluorescent 204 
Ca2+ indicator dye (Molecular Probes, Eugene, OR, USA) until a spontaneous 205 
myogenic tone developed. Intracellular Ca2+ concentrations were measured with an 206 
Incyte IM system (Intracellular Imaging Inc, Cincinnati, OH, USA). Fura-2 207 
fluorescence (recorded every 2-5 s) was excited alternately by 340 and 380-nm light, 208 
and the emitted fluorescence was detected above 510 nm. The outer arteriolar 209 
diameter was determined in each recorded image. Arteriolar Ca2+ concentration was 210 
determined as the Fura-2 fluorescence ratio (F340/380). 211 
 212 
Immunohistochemistry 213 
The gracilis muscle was removed from the rat and embedded in Tissue-Tek O.C.T 214 
compound (Electron Microscopy Sciences; Hatfield, PA, USA). Cryostat sections (10-215 
µm-thick, Electron Microscopy Sciences; Hatfield, PA, USA) were prepared, fixed in 216 
acetone for 5-10 min and blocked with normal goat sera for 20 min (1.5% in PBS, 217 
Sigma-Aldrich; St. Louis, MO, USA). COX enzymes were stained with COX-1 (Rabbit 218 
anti COX1: ab109025, dilution: 1:50) and COX-2-specific antibodies (Rabbit anti-219 
COX2: ab15191, dilution: 1:50). Antibodies were visualized through the use of 220 
fluorescent secondary antibodies (Goat anti-rabbit biotin, dilution: 1:100; goat anti-221 
mouse FITZ, dilution: 1:300). Gracilis muscle was co-stained with anti-smooth muscle 222 




(Vector Laboratories, Burlingame, California, USA). Pictures were processed by ImageJ 224 
software (NIH, Bethesda, MD, USA).  225 
 226 
Measurement of inhibitory effect of L-Met on the chlorinating activity of MPO 227 
MPO-evoked chlorinating activity was measured with a commercial assay kit 228 
(Cayman Chemical Company, Ann Arbor, MI, USA) in accordance with the 229 
manufacturer’s instructions. The measurement is based on the cleavage of 230 
nonfluorescent 2-[6-(4-aminophenoxy)-3-oxo-3H-xanthen-9-yl] benzoic acid (APF) to 231 
fluorescein by MPO-generated hypochlorite (-OCl). The reaction mixtures contained 232 
45 µM APF, 30 µM H2O2, 3 U l
-1 MPO and 200-0.39 mM L-Met (serially diluted). The 233 
measurements were performed in phosphate-buffered saline (PBS, pH=7.4) 234 
independently from the in vitro vascular experiments. Changes in fluorescence 235 
intensity (λex=485 nm, λem=520 nm) were measured at 30-s intervals for 5 min with a 236 
plate reader (NovoStar plate reader, BMG Labtech). Fluorescence intensities values 237 
were plotted as a function of time and fitted by linear regression (before saturation). 238 
The slope of this relation was used to calculate MPO activities. 239 
 240 
Data analysis and statistical procedures 241 
The internal diameters of arterioles are shown as means±SEM. Arteriolar constriction 242 
was expressed as the change in diameter as a percentage of the initial diameter 243 
(before addition of the vasoactive agents) measured at an intraluminal pressure of 80 244 
mmHg. Arteriolar dilation was calculated as the percentage of the maximal (passive) 245 
diameter determined in the absence of extracellular Ca2+ at the end of the 246 
experiments. The contractile force was indicated in absolute values, as the difference 247 




performed with Microsoft Office Excel software by the Student’s t-test. P<0.05 was 249 
considered statistically significant. 250 
 251 
Results 252 
MPO promotes H2O2-evoked vasoconstriction 253 
MPO (1.92 mU ml-1) increased the vascular tone, and promoted the development of 254 
vasoconstriction in the presence of H2O2 in vascular beds of different origin. In the 255 
SMAs, a robust MPO-dependent vasoconstrictive effect was observed, i.e. from a 256 
50±21% level of vasodilation (at 1 mM H2O2), to 47±11% vasoconstriction following 257 
the addition of MPO (P=0.004; Fig. 1A). In the CAs, where H2O2 evoked only 258 
vasodilation, MPO administration resulted in significant vasoconstriction in a wide 259 
range of H2O2 concentrations, e.g. 13±4% dilation at 100 μM H2O2, but 6±3% 260 
constriction following the addition of MPO (P=0.006; Fig. 1B). In the BAs, the MPO-261 
dependent vasoconstriction was relatively less pronounced e.g. 1.1±0.5 mN dilation 262 
at 100 µM H2O2 and 1.6±0.7 mN constriction following the addition of MPO (P<0.05; 263 
Fig. 1C). Vascular diameters measured under various test conditions are to be seen 264 
in Tables 1 and 2. 265 
MPO alone (without the addition of its substrate H2O2) did not affect the 266 
diameters of the SMAs or the CAs or the contractile force in the BAs (data not 267 
shown). 268 
 269 
HOCl mediates the MPO-induced vasoconstriction in the SMAs 270 
The mechanical effects of the chlorinating activity of MPO were assessed comparing 271 
the vascular responses in the presence of the HOCl scavenger L-Met (100 µM) with 272 




(Fig. 2A and 2B). The extracellular concentration of H2O2 can reach as high as 300 274 
µM in vivo, and our studies were therefore highlighted at this H2O2 concentration. The 275 
MPO-specific inhibitor prevented the development of MPO-dependent 276 
vasoconstriction (maximal vasoconstriction at 300 µM H2O2+MPO: 47±7% vs. 16±6% 277 
vasoconstriction, P<0.0001) as expected. In the presence of L-Met, however, the 278 
MPO induced-vasoconstrictions were converted to robust vasodilations (e.g. to 279 
73±11% dilation at 300 µM H2O2, P<0.0001 vs. MPO+H2O2) suggesting an MPO-280 
evoked, but HOCl-independent vasodilation mechanism. L-Met (100 µM) alone did 281 
not affect the H2O2-evoked vasoconstriction in the absence of MPO (Fig. 2C). In a 282 
parallel in vitro enzyme assay, 100 µM L-Met fully opposed the chlorinating activity of 283 
MPO (Fig. 2D). 284 
 285 
Divergent effects of L-Met treatments on MPO-evoked vasodilations in different 286 
vessel types 287 
The MPO-stimulated HOCl-independent vasodilating mechanism was screened in 288 
different vascular beds (Fig. 3). In the SMAs, the above mechanism exhibited an 289 
apparent L-Met concentration dependence (maximal vasoconstriction at 300 µM 290 
H2O2 47±7% vs. vasodilations of 8±19%, 35±23%, and 73±11% in the presence of 291 
20, 40 and 100 µM L-Met, respectively; Fig. 3A and 3B). In the CA, the maximal L-292 
Met concentration (100 µM) also provoked vasodilation at a high (1 mM) H2O2 293 
concentration, whereas at 300 µM H2O2 L-Met did not modulate the vascular tone 294 
(i.e. 3±9% vs. 13±7% vasodilation; P=0.44, Fig. 3C and 3D). Finally, 100 µM L-Met 295 
treatment did not significantly influence the MPO-evoked vascular responses in the 296 
BAs (e.g. 3.3±1 mN vasoconstriction at 300 µM H2O2 vs. 4.0±1 mN vasoconstriction, 297 




The signaling mechanism of MPO-evoked vasoconstriction in the SMAs 299 
Endothelium removal inhibited the MPO-evoked vasoconstriction in the SMAs (e.g. 300 
47±7% vasoconstriction at 300 µM H2O2+MPO with intact endothelium, vs. 13±15% 301 
vasoconstriction + MPO without endothelium, P=0.07; Fig. 4A). 302 
Next, the involvement of the TXA2 receptors in the MPO-evoked 303 
vasoconstrictive effects was tested. Inhibition of the TXA2 receptors by 1 µM SQ-304 
29548 converted the MPO-evoked vasoconstrictions to vasodilations (e.g. 47±7% 305 
vasoconstriction at 300 μM H2O2+MPO vs. 30±17% dilation at 300 µM 306 
H2O2+MPO+TXA2 receptor inhibitor; P=0.002, Fig. 4B). 307 
The role of COXs in the MPO-evoked vascular responses was also examined 308 
by using the nonspecific COX inhibitor indomethacin (1 µM); similarly to TXA2 309 
inhibition, this not only prevented the MPO-evoked vasoconstriction, but converted it 310 
that to vasodilation (47±7% vasoconstriction at 300 µM H2O2 vs. 69±16% 311 
vasodilation; P=0.002; Fig. 4C). 312 
 313 
Vascular expression of COXs in the SMAs 314 
The expression of COX isoenzymes in SMAs was tested by immunohistochemistry. 315 
Both the vascular smooth muscle layer and the endothelial cells were stained 316 
positively with the anti-COX-1 antibody, whereas the anti-COX-2 antibody did not 317 
produce a COX-specific staining pattern (Fig. 5). 318 
 319 
MPO-induced vasoconstriction develops in the absence of significant 320 
intracellular Ca2+ concentration changes 321 
Measurements of the intracellular Ca2+ concentration and the arteriolar diameter 322 




(29±3% vasoconstriction at 1 mM H2O2; P=0.04 vs. the baseline) developed without 324 
significant changes in the F340/380 ratio signal in the range of H2O2 concentrations 325 
between 1 µM and 1 mM (Fig. 6A). In contrast, the norepinephrine-evoked (1 nM-10 326 
µM) vasoconstrictions with comparable magnitudes (44±4% constriction at 10 µM 327 
norepinephrine; P=0.0005 vs. the baseline) were accompanied by significant 328 
increases in the F340/380 ratio (from 0.85±0.03 to 1.15±0.09; Fig. 6B). MPO alone did 329 
not have any effect on the arteriolar diameter or on the F340/380 signal (not shown). 330 
 331 
Discussion 332 
Vascular inflammation during endothelial dysfunction (Zhang et al., 2001a), 333 
atherosclerosis (Sugiyama et al., 2001, Sirpal, 2009, Woods et al., 2003, Ford, 2010) 334 
diabetes mellitus (Zhang et al., 2004, Kataoka et al., 2014), coronary artery disease 335 
(Cavusoglu et al., 2007, Mayyas et al., 2014) is characterized by increased levels of 336 
production and local release of both H2O2 and MPO. Moreover the increased 337 
generation of MPO was observed in neurodegenerative disorders (Reynolds et al., 338 
1999, Pennathur et al., 1999), arthritis (Bender et al., 1986) and some cancers 339 
(Reynolds et al., 1997). We hypothesized that MPO evokes substantial vasomotor 340 
responses in the presence of H2O2. This process may have immediate (acute) effects 341 
on the vascular diameter, which was tested here under in vitro conditions. The details 342 
of intracellular mechanisms responsible for the MPO elicited vasomotor responses 343 
were studied in SMAs. The most important findings of this study are that (1) MPO has 344 
the potential to promote vasoconstriction in H2O2-treated SMAs, CAs or BAs of the 345 
rat; (2) in the SMAs, MPO facilitates the H2O2-dependent activation of COX-1 and the 346 




the smooth muscle cells; and (3) L-Met inhibits the chlorinating activity of MPO, and 348 
converts MPO-evoked vasoconstrictions to vasodilations in the SMAs. 349 
The question arises as to whether the observed decreased vasodilation in the 350 
presence of MPO originates from H2O2 consumption by MPO, thereby requiring a 351 
higher nominal H2O2 concentration to produce comparable vasodilations. At lower 352 
concentrations of H2O2, the level of vasoconstriction was similar in the absence and 353 
in the presence of MPO, while at higher concentrations of H2O2 MPO led to higher 354 
maximal vasoconstriction levels, thereby suggesting that MPO did not simply shift the 355 
apparent H2O2 concentration dependences of the vascular responses. We therefore 356 
postulate alternative mechanisms for the explanation of the MPO-dependent vascular 357 
effects. 358 
One of the major products of the MPO-mediated conversion of H2O2 is HOCl. 359 
Our in vitro vascular measurements were performed in Ca2+ containing Krebs 360 
solution which provided the chloride ions for the MPO to generate HOCl. The 361 
mechanisms through which HOCl can affect vascular tissues have been examined by 362 
a number of research groups. HOCl initiates the halogenation, nitration and oxidative-363 
crosslinking of amino acids, lipids and nucleotides (Prutz, 1996, Albrich et al., 1981). 364 
Less is known about the molecular pathways involved in the HOCl-evoked changes 365 
in vascular dynamics. One such possibility relates to a decrease in NO bioavailability, 366 
as suggested by observations on HOCl-dependent impairments in endothelial 367 
function (Yang et al., 2006, Stocker et al., 2004, Xu et al., 2006). Similarly to our 368 
findings, HOCl was found to cause vasoconstriction in bovine pulmonary arteries, but 369 
the exact mechanism of this effect remained unclear (Turan et al., 2000). The present 370 
investigation revealed increases in vasoconstriction in the SMAs, CAs and BAs, 371 




additionally made an effort to identify the molecular mechanisms contributing to these 373 
vasoconstrictive effects, besides to the decreased NO bioavailability reported earlier. 374 
One of the major observations was that the widely accepted HOCl scavenger L-Met 375 
(Okabe et al., 1993, Zhang et al., 2003, Zhang et al., 2004) not only inhibited the 376 
vasoconstriction evoked by MPO, but also unmasked a robust vasodilatory effect in 377 
the SMAs. The employed MPO-specific inhibitor, 4-aminobenzhydrazide blocked 378 
both the chlorinating and the peroxidase activities of the MPO (Malle et al., 2007, 379 
Kettle et al., 1995, Kettle et al., 1997) and prevented the vasoconstriction evoked by 380 
MPO. In the presence of 4-aminobenzhydrazide and MPO however, the vascular 381 
responses to H2O2 did not differ significantly from those in the absence of MPO. 382 
Collectively, the above data suggested that MPO-mediated chlorination has a major 383 
role in the activation of a signaling pathway leading to vasoconstriction. L-Met not 384 
only antagonized this effect, but revealed an additional MPO-dependent mechanism 385 
leading to vasodilation. This latter effect was probably related to the peroxidase 386 
activity of MPO that was not inhibited by L-Met. It is worthy of consideration that in 387 
the CAs and BAs, where MPO evoked vasoconstrictions were less pronounced than 388 
those in the SMAs, L-Met did not result in significant vasodilations, which is 389 
suggestive of differential expressions of the MPO-responsive vasodilatory pathways 390 
in the different vascular beds. 391 
Effector structures responding to MPO-derived radicals were first tested by 392 
removal of the endothelium in SMAs, which eliminated the endothelium-derived 393 
effects, including decreased NO bioavailability (Stocker et al., 2004, Xu et al., 2006, 394 
Turan et al., 2000). Importantly, H2O2-evoked vasoconstrictions were found in a 395 
previous study to be completely endothelium-dependent (Csato et al., 2014). 396 




partially opposed by endothelium removal (Fig. 4A), suggesting that the MPO-evoked 398 
vasoconstriction was only partially endothelium-dependent. These observations, 399 
together with those in the presence of the COX inhibitor indomethachin and the TXA2 400 
inhibitor SQ-29548, implicate that MPO causes the generation of a vasoconstrictive 401 
prostanoide derivate (potentially TXA2) not only in the endothelial cells, but also in 402 
the vascular smooth muscle cells, through the activation of COXs. To confirm this 403 
possibility, the expression of COXs enzymes was explored by means of 404 
immunohistochemistry, and COX-1-specific staining was indeed confirmed both in 405 
the endothelial layer and in the smooth muscle cells of the SMAs. Interestingly, not 406 
only was the MPO-mediated vasoconstriction prevented by either TXA2 receptor 407 
inhibition or COX inhibition, but similarly as when L-Met was applied it was converted 408 
to vasodilation. A role for TXA2 was implicated by its pharmacological inhibitor, 409 
nevertheless we did not examine TXA2 production upon MPO exposures. Taken 410 
together, we postulate that the MPO-evoked vasoconstriction is mediated by a 411 
vasoconstrictive prostanoid derivative through TXA2 receptor activation. Hence, the 412 
above findings point to a HOCl – COX1 – TXA2 pathway as being decisive in the 413 
prevention of MPO-dependent vasodilation in the SMAs (Fig. 7). 414 
Numerous previous studies have furnished evidence that H2O2 is an important 415 
regulator of the vascular diameter (Matoba et al., 2000, Yada et al., 2003, Matoba et 416 
al., 2003, Koller and Bagi, 2004, Miura et al., 2003, Gao and Lee, 2005, Gao et al., 417 
2003, Gao and Lee, 2001). It is difficult to specify the physiologic concentration of 418 
H2O2 in vascular tissues in vivo. Nevertheless, it has been found that under 419 
pathologic conditions it may increase up to 0.3 mM. In our study, H2O2 was used in a 420 
wide concentration range (1 μM-10 mM), thus covering also pharmacological levels. 421 




developing on top of the biphasic H2O2 dependent responses (Liu and Zweier, 2001, 423 
Root and Metcalf, 1977, Cseko et al., 2004). In higher concentrations H2O2 may 424 
cause vasodilation. The possible mechanism of the H2O2-evoked vasodilation has 425 
been investigated by a number of groups in different vessel types (Iida and Katusic, 426 
2000, Thengchaisri and Kuo, 2003, Zhang et al., 2012). Our previous results 427 
implicated the involvement of the NO/cyclic guanosine monophosphate pathway and 428 
the activation of K+ channels in SMAs (Cseko et al., 2004). 429 
Under pathological conditions associated with inflammation, such as acute 430 
infections (Hampton et al., 1998, Pullar et al., 2000, Hirche et al., 2005), diabetes 431 
(Zhang et al., 2004, Kataoka et al., 2014), atherosclerosis (Sugiyama et al., 2001, 432 
Sirpal, 2009, Woods et al., 2003, Ford, 2010), arthritis (Bender et al., 1986), 433 
Alzheimer disease (Reynolds et al., 1999), and Parkinson disease (Pennathur et al., 434 
1999) MPO is released together with H2O2. In vivo conditions, MPO is released 435 
together with H2O2. Under these circumstances L-Met may prevent H2O2-evoked 436 
vasoconstriction or even convert it into vasodilation, because L-Met in its presumed 437 
physiological concentration range (i.e. 20-40 µM) (Mayo Medical Laboratories, 2015) 438 
also largely prevents the vasoconstrictions evoked by MPO in the SMAs. Hence, the 439 
ultimate effect on the vascular tone and thereby on local microcirculation will be a 440 
function of the availability of a range of local regulators (e.g. H2O2, MPO, L-Met, etc.) 441 
which are of high potency in vasoregulation (Cseko et al., 2004).  442 
The MPO-induced vasoconstrictions were not accompanied by significant 443 
increases in the intracellular Ca2+ concentration in the H2O2 concentration range of 444 
between 100 µM and 1 mM. In contrast, norepinephrine treatment evoked 445 
vasoconstrictions to similar degrees, together with significant increases in the 446 




A2 receptor agonist U46619) activated a Ca2+-sensitizing mechanism, causing 448 
vasoconstriction rather than increasing the intracellular Ca2+ concentration (Csato et 449 
al., 2014). The mechanism of MPO-mediated vasodilation was beyond the scope of 450 
this study. 451 
Overall, our present results suggest that MPO-derived HOCl can enhance the 452 
production of a TXA2-like vasoconstrictive molecule both in the endothelium and in 453 
the vascular smooth muscle cells of SMAs, thereby increasing the sensitivity of the 454 
contractile protein machinery in the vascular smooth muscle cells to produce 455 
vasoconstriction. Nevertheless, in the absence of a functional HOCl – COX1 – TXA2 456 
pathway, an MPO dependent vasodilatory mechanism may prevail in the SMAs of the 457 
rat during tissue inflammation associated with neutrophil degranulation. 458 
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Study limitations 464 
In this study we aimed to explore the effects of MPO and H2O2 in vascular 465 
preparations with different origins. Due to differences in vascular diameters for SMAs, 466 
CAs and BAs: (i.e. ~160 μm, ~180 μm, ~250 μm, respectively) the same 467 
experimental set-up could not be employed for all vascular beds. Prior test 468 
incubations, spontaneous myogenic tone developed in isotonic preparations (SMAs 469 
and CAs), while during isometric measurements (BAs) agonist induced constrictions 470 
were applied. Consequently, the extent of the observed vascular responses may 471 




vascular responses (vasodilation vs. vasoconstriction) could be determined 473 
convincingly because results were contrasted to controls under the same 474 
experimental conditions. 475 
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 676 
Significance 677 
Cardiovascular diseases are associated with inflammation and increased oxidative 678 
stress. An understanding of the physiological responses as concerns pro-oxidant 679 
mechanisms may contribute to the development of new and more effective drugs in 680 
the fight against cardiovascular diseases. The most important message of this paper 681 
is that L-Met not only has the potential to prevent the vasoconstrictive responses due 682 
to activation of the HOCl - COX1 - TXA2 pathway, but can evoke pronounced 683 
vasodilations in the presence of the proinflammatory enzyme MPO. 684 
Tables 685 
Table 1. Effects of different inhibitors and endothelium removal on the MPO- 686 
and H2O2-induced arteriolar responses 687 
Tissue sources of arteriolar beds are indicated (CAs or SMAs). Diameters are shown 688 
as means±S.E.M. in absolute values (µm). The number of experiments performed is 689 
also indicated. Arteriolar diameters are given at the beginning of the experiments 690 
(initial diameter) and after treatment with 100 µM (the maximum constrictor dose in 691 
the control) or 10 mM (the maximum dilator dose in the control) H2O2. The effects of 692 
preincubations with inhibitors (diameter after the inhibitor) and the maximum diameter 693 
of the vessels (the passive diameter) are also indicated. 694 
Table 2. Effects of different treatments on the MPO-and H2O2-induced changes 695 




Force values are given as means±S.E.M. in absolute values (mN). The number of 697 
experiments performed is also indicated. Contractile forces refer to the beginnings of 698 
the experiments (initial force), after precontraction with KCl (10 mM or 60 mM), and 699 























100 µM L-Met 100 µM L-Met 
MPO+ 
40 µM L-met 
MPO+ 
20 µM L-Met 
MPO+4-amino-
benzhydrazide 
No. of experiments 5 4 5 5 5 5 5 5 4 6 5 
Initial diameter 180±17 85±15 182±12 136±15 171±7 178±8 115±23 123±8 151±9 183±25 188±7 
Diameter after inhibitor - 76±12 - 141±14 - 166±7 112±20 - 143±12 176±25 - 
Diameter after MPO 190±16 73±9 182±12 142±13 172±7 168±8 115±19 120±14 143±13 175±24 181±8 
Diameter after 1 mM H2O2 191±12 105±15 93±17 171±19 179±6 193±8 175±22 168±13 184±18 191±26 143±28 











100 µM L-Met 
No. of experiments 5 5 
Initial force 5.5±1.70 0.55±0.65 
Force after 10 mM KCl 1±0.47 0.52±0.41 
Force after 60 mM KCl 9.97±1.41 7.16±1.41 
Force after MPO 9.97±1.41 8.02±1.59 















Figure 1. MPO promotes H2O2-evoked vasoconstriction in different vascular 
beds 
After preincubation with MPO (activity: 1.92 mU ml-1, 600 s), isolated, cannulated 
SMAs (initial diameter (id): 182±12 μm, n=5 arterioles from 4 different animals; panel 
A) or CAs (id: 180±17 μm, n=5 arterioles from 5 different animals; panel B) with intact 
endothelium were treated with increasing concentrations (1 µM-10 mM) of H2O2. In 
SMAs H2O2 alone (10 μM, 30 μM and 100 μM) evoked significant vasoconstriction 
compared to the zero line (P<0.02). In the presence of MPO, H2O2 caused significant 
vasoconstriction from 10 μM-1 mM H2O2 compared to the control and the zero line 
(P<0.05, panel A) In CAs H2O2 (30 μM and 100 μM) and MPO evoked significant 
vasoconstriction comparing to the control (P<0.05) which was not significant 
compared to the baseline (panel B) The arteriolar diameter was recorded and 
cumulative concentration-response relationships were determined. Changes in 
relative arteriolar diameter are shown. Values during vasodilations are expressed as 
percentages of the difference between the maximal passive diameter (maximal 
dilation (100%) in the absence of extracellular Ca2+) and the initial diameter, while 
constriction is expressed as a percentage of the initial diameter (illustrated at 0% on 
the y scale). Similarly, isolated BAs (n=5 arterioles from 5 different animals) 
precontracted with KCl were incubated in the presence of MPO (activity: 1.92 mU ml-
1, 600 s). Arteries were exposed to the increasing concentrations of H2O2 (1 µM-3 
mM, panel C). H2O2 evoked vasoconstriction was significant at 30 μM, whereas in the 
presence of MPO the vasoconstriction was significant at 10 μM, 30 μM and 100 μM 
H2O2 compared to the baseline. MPO and H2O2 caused significant vasoconstriction 





are indicated in absolute values, as differences from the initial baseline force. 
Asterisks denote significant differences from the control (H2O2 without MPO). 
Figure 2. HOCl mediates the vasoconstriction evoked by MPO in the SMAs 
MPO induced vasoconstriction was inhibited with the MPO inhibitor 4-
aminobenzhydrazide (50 µM) (id: 182±8 µm, n=5 arterioles from 4 different animals; 
closed triangles), however significant vasoconstriction was still observed at 100 μM 
and 300 μM (P<0.05) compared to the baseline Panel A). 100 µM L-Met converted 
the MPO-induced vasoconstriction to vasodilation (id: 115±19 µm, n=5 arterioles from 
5 different animals; closed squares). Open circles represent the effects of H2O2 
alone, while closed circles illustrate the effects of H2O2 in the presence of MPO. 
Asterisks denote significant differences from the MPO, and crosses significant 
differences between MPO+MPO inhibitor and MPO+L-Met. The effects of MPO alone 
and in combination with the MPO inhibitor or L-Met in the presence of 300 µM H2O2 
(control) on the vascular diameter in the SMAs (Panel B). The H2O2-induced biphasic 
response did not change in the presence of 100 µM L-Met (id: 120±14 µm, n=5 
arterioles from 5 different animals; closed squares, but it caused significant 
vasoconstriction relative to the zero line at 10 μM and 30 μM H2O2; Panel C). 
Increasing concentrations of L-Met inhibited the chlorinating activity of MPO in a 
concentration-dependent manner (100%: maximal activity without L-Met, Panel D). 
Figure 3. Effects of L-Met on the MPO-mediated vascular effects in different 
arteriolar beds 
Increasing concentrations of L-Met (20, 40 or 100 µM) inhibited the MPO-mediated 
vasoconstriction in the SMAs in concentration-dependent manner (Id: 175±24 µm, 





143±13 µm, n=4 arterioles from 4 different animals, with 40 µM L-methionine, (open 
triangles), id: 115±19 µm, n=5 arterioles from 5 different animals, with 100 μM L-Met 
(open squares). MPO and 20 µM L-methionin evoked significant vasoconstriction at 
10 μM H2O2 compared to the baseline; Panel A). The effects of MPO alone and in 
combination with increasing L-Met concentrations in the presence of 300 µM H2O2 
(control) on the vascular diameter in the SMAs (Panel B). In the CAs L-Met (100 µM; 
open squares) inhibited the MPO-evoked vasoconstriction only at a higher 
concentration of H2O2 (id: 73±10 µm n=4 arterioles from 4 different animals). 
Asterisks denote significant differences from MPO (Panel C). The effects of MPO 
alone and in combination with 100 µM L-Met in the presence of 300 µM H2O2 
(control) on the vascular diameter in the CAs (Panel D). L-Met (100 µM; open 
squares) did not significantly influence the MPO-evoked changes in the isometric 
force in the BAs compared to the control (n=6 arterioles from 3 different animals, 
Panel E), but comparing to the zero line MPO together with L-met caused significant 
vasoconstriction at 30 μM and 100 μM H2O2 (P=<0.05). The effects of MPO alone 
and in combination with 100 µM L-Met in the presence of 300 µM H2O2 (control) on 
the vascular diameter in the BAs (Panel F). 
Figure 4. The mechanism of MPO-induced vasoconstriction in the SMAs 
H2O2-evoked vasoconstriction (open circles; control) was abolished after endothelium 
denudation (id: 138±10 µm, n=4 arterioles from 4 different animals; closed diamonds, 
Panel A). However, in the presence of MPO, and at relatively low H2O2 
concentrations, vasoconstrictions (significant vasoconstriction at 10 μM -100 μM 
H2O2 compared to the baseline; P<0.05). were still observed in the absence of 
endothelium (id: 172±7 µm, n=5 arterioles from 4 different arterioles; open triangles). 





from the action of MPO in the presence and absence of endothelium, and crosses 
indicate significant differences between the endothelium removal and the control. 
The MPO and H2O2-induced vasoconstriction was tested in the presence of the TXA2 
receptor antagonist (id: 142±13 µm, n=5 arterioles from 4 different animals; closed 
triangles, Panel B) and in the presence of the COX inhibitor (id: 168±8 µm, n=5 
arterioles from 3 different animals; open triangles, Panel C). Asterisks denote 
significant differences from MPO.  
 
Figure 5. COX-1 isoenzyme is present in the vascular endothelial and smooth 
muscle cells in the SMAs 
The presence of COX-1 isoenzyme in the vascular smooth muscle cells and in the 
vascular endothelium was confirmed by immunohistochemistry. Smooth muscle actin 
is labeled in green, COX in red, and nuclei in blue (from top to bottom). Control 
images (without primary antibodies) are indicated in the right-hand column. 
 
Figure 6. MPO increases the Ca
2+ sensitivity of force production in the vascular 
smooth muscle cells 
The changes in intracellular Ca2+ levels (F340/380 signals) and external arteriolar 
diameters were studied in SMAs under control conditions (id: 297±9 µm, n=7 
arterioles from 6 different animals; panel A), or after treatment with norepinephrine 
(id: 314±16 µm, n=7 arterioles from 6 different animals; panel B). Asterisks denote 
significant differences from the initial values. 
Figure 7. A proposed mechanism for the vascular effects of MPO in the SMA 
During its anti-inflammatory activity, MPO modulates the vascular action of H2O2. The 





the generation of thromboxane A2 (TXA2) both in endothelial cells and in vascular 
smooth muscle cells, leading to vascoconstriction through a Ca2+-sensitizing 
mechanism in vascular smooth muscle cells. An MPO inhibitor prevents both the 
peroxidation and the chlorinating activity, while L-Met inhibits only the chlorinating 
activity of the enzyme. In the presence of L-Met, the peroxidation pathway is still 
functional and vasodilation is observed, probably due to the generation of a 
vasodilatative peroxidation product (marked by a question mark).  
 
 
 
